Survodutide vs Retatrutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicSurvodutideRetatrutide
What it is

An investigational glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, also known as BI 456906.1,6

An investigational agonist of the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly and also known as LY3437943.4,7

FDA status

In clinical trials

In clinical trials; not FDA-approved1,2,3

Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.3

Is survodutide FDA-approved?

In clinical trials

In clinical trials; not FDA-approved3,4,5

Not FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.3

Is retatrutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.8

Not among the six peptides the policy lists.8

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial SYNCHRONIZE-1, a 76-week blinded, randomized, placebo-controlled Phase 3 trial in 725 adults with obesity, or overweight with a related condition, that excluded diabetes, published in The New England Journal of Medicine.9
  • Large randomized human trial A 46-week randomized, double-blind, placebo-controlled Phase 2 trial that treated 386 adults with overweight or obesity without diabetes, published in The Lancet Diabetes & Endocrinology.6
  • Controlled human trial A 48-week randomized, placebo-controlled Phase 2 trial that treated 293 adults with biopsy-confirmed MASH and liver fibrosis, published in The New England Journal of Medicine.10
  • Controlled human trial SYNCHRONIZE-MASLD, a 48-week blinded, randomized, placebo-controlled Phase 3 trial in 216 treated adults with obesity and fatty liver disease, published in Nature Medicine.11
  • Registered trial without results SYNCHRONIZE-CVOT (NCT06077864), a Phase 3 cardiovascular safety trial in people with overweight or obesity, listed as completed in its August 11, 2026 registry record. Its results are not part of the sources cited here.12

Large randomized human trials

  • Large randomized human trial A 48-week double-blind, randomized, placebo-controlled Phase 2 trial in 338 adults with obesity, or overweight with a weight-related condition, published in The New England Journal of Medicine.13
  • Controlled human trial A randomized, double-blind Phase 2 trial with placebo and active comparator groups in 281 adults with type 2 diabetes at 42 U.S. centers, published in The Lancet.14
  • Large randomized human trial TRANSCEND-T2D-1, a 40-week double-blind, randomized, placebo-controlled Phase 3 trial in 537 adults with type 2 diabetes, published in The Lancet.7
  • Registered trial without results Phase 3 trials in obesity with cardiovascular disease (NCT05882045) and in obesity with type 2 diabetes or sleep apnea (NCT05929079), listed as completed in registry records updated July 30, 2026. Their results are not part of the sources cited here.15,16
  • Registered trial without results A Phase 3 trial in people with cardiovascular or chronic kidney disease (NCT06383390), listed as active, not recruiting in its August 24, 2026 registry record.17
Records collected

13 ClinicalTrials.gov records and 4 PubMed records collected

8 ClinicalTrials.gov records and 17 PubMed records collected

Area of study

Metabolic and weight, Liver1

Metabolic and weight4

Latest dated events
  1. FDA’s page on unapproved GLP-1 drugs, which names survodutide among drugs sold with false research-use labels, is updated, as shown by its content-current date.3
  2. Results of the Phase 3 trials SYNCHRONIZE-1 and SYNCHRONIZE-MASLD are published.9,11
  3. Results of Phase 2 trials in obesity and in MASH with fibrosis are published.6,10
  1. FDA’s page on unapproved GLP-1 drugs, which says retatrutide cannot be used in compounding, is updated, as shown by its content-current date.3
  2. Results of TRANSCEND-T2D-1, a Phase 3 trial in type 2 diabetes, are published in The Lancet.7
  3. Results of two Phase 2 trials, in obesity and in type 2 diabetes, are published.13,14

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  3. 3
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  5. 5
    ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  6. 6
    Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (2024) · PMID 38330987 ↗

    The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026

  7. 7
    Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026) · PMID 42250575 ↗

    The Lancet · Official source · Source checked November 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1, 2026) · PMID 42253238 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  10. 10
    A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024) · PMID 38847460 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  11. 11
    Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (2026) · PMID 42252333 ↗

    Nature Medicine · Official source · Source checked November 14, 2026

  12. 12
    ClinicalTrials.gov record NCT06077864 · retained source version 2026-08-11:60e24ca2b3858aa7bfd06f0e1cac79051207229d8181cdbe15a0399bddf60984 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  13. 13
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023) · PMID 37366315 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  14. 14
    Retatrutide for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (2023) · PMID 37385280 ↗

    The Lancet · Official source · Source checked November 14, 2026

  15. 15
    ClinicalTrials.gov record NCT05882045 · retained source version 2026-07-30:d21e38ddcccc7ab66ec1bddaa910bf3c7a7a3149a43f4ac27918a9e80f8452da ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  16. 16
    ClinicalTrials.gov record NCT05929079 · retained source version 2026-07-30:d0cad2c0ebfa7ce1f2af088a52c397680123509e21999e7837a0b2b517e9ef04 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  17. 17
    ClinicalTrials.gov record NCT06383390 · retained source version 2026-08-24:4bb37a90f79acd41fc8e0a5c8b4745c3c9610a0993eab8f502e836929a21c5ff ↗

    ClinicalTrials.gov · Official source · Source checked September 9, 2026